Glenmark Pharmaceuticals Limited — Updates, 14-11-2024: Press Release

Glenmark Pharmaceuticals has reported a solid performance in Q2 FY 2024-25, with consolidated revenue reaching ₹34,338 Mn, reflecting a 7.1% year-on-year increase. Notable revenue growth was seen in the Europe segment, which grew by 14.6% to ₹6,874 Mn, and the India business, which increased by 13.9% to ₹12,817 Mn. The company’s EBITDA rose by 30.2% to ₹6,019 Mn, solidifying an EBITDA margin of 17.5%. Profit After Tax (PAT) also saw an improvement, rising to ₹3,545 Mn, registering a PAT margin of 10.3%.

Strategically, Glenmark is enhancing its product offerings with promising new therapies, particularly in the respiratory sector. Their flagship product RYALTRIS® has been commercialized in numerous markets, and significant milestones have been achieved in expanding its global footprint. Additionally, the company is preparing to present promising data on their innovative biologic asset, ISB 2001, at an upcoming hematology conference.

Looking ahead, Glenmark is focused on sustaining its growth trajectory and capitalizing on emerging opportunities in therapeutic markets. Investors should keep a close watch on the company’s continued advancements in product development and market capture.